FDA alarms on birth-control pills as a high risk of blood clot formation

The United States Food and Drug Administration (FDA)—“remains concerned” over certain contraceptive pills that includes “drospirenone” that might raise a high risk of blood clots.

     

During a drug safety announcement on the agencies webpage, in the preliminary study Food and Drug Administration (FDA), founded a result suggests an increase of 1.5-fold threat of blood clots in the women who use birth control pills containing Bayer, as compared to the users of other hormonal birth control pills.

Bayer best selling drug, generic Yasmin and generic Yaz includes “drospirenone” that is a sort of sex hormone in females known as progestin, also accessible in it generic form.

Food and Drug Administration (FDA), has still not reached to a conclusion, weather only these products have a high risk of developing blood clots over the other pills. FDA has set up a external board of medical experts to talk about the issue.

Nearly all the contraceptive pills include 2 types of hormones progestin and estrogen. Hence all the pills raise a risk of blood clots and contain a warning label.

But according to FDA there is contradicting information over the risk of blood clot; most probably it is linked with drospirenone. Apart from this, there are six other studies published over the blood clot risk. Like some have reported that the formation blood clot is due to the used of drospirenone in the pills where as some say, use of levonorgestrel in the birth control pills also have the same risk. Whereas the risk of blood-clots is less among those women who intake birth-control medicine, the Food and Drug Administration (FDA) suggests that women’s who aren't consuming these pills are at the higher risk.

FDA initiates to update New Guidelines to Improve Quality of Clinical Trials

Food and Drug Administration (FDA) has issued a guidance draft, to improve the clinical trial for researchers and manufacturers for a much superior quality check in support of premarket approval (PMA) request for medical plans.

This draft will include new guidelines regarding; new regulation, new guidance for development, upgrading FDA's internal quality check, Clinical Trial Transformation Initiative (CTTI) - require modernizing the clinical trial project, improving the training of the health authorities in context to inspection of the clinical check and modernization of regulation. FDA has also been improving its report on of violative inspection and functioning to recognize substitute methods to choose the clinical researcher for inspection.

The newly proposed guideline designed for clinical trial includes; setting proper study aims, reducing data bias, and choose a correct study site and participants. FDA has implemented total 25 action plans to strengthen the process, improve the certainty and transparency in the regulatory trial.

Food and Drug Administration (FDA) want to lend a helping hand to the manufacturers and the researchers, to manage a secure and an efficient product in the market without any burden.

This proposed guideline will help manufacturers and researchers for enhanced their understanding towards, FDA's vital expectations from clinical trials. FDA's is encouraging researchers to get in touch and discuss the most sensible move toward to studying their device."
generic viagra
Today these draft guidelines will help manufacturers and researchers to design a essential study related to their assets of effort, time, and capital so that they have high possibility of representing the security and the effectiveness of their product.

Vivus’s NDA accepted by FDA for Avanafil (and ED drug)

Vivus Inc. has declared that the U.S. Food and Drug Administration have accepted for review the company's new drug application or NDA. FDA would be reviewing Vivus Inc.’s investigational drug candidate called avanafil for treating the problem of erectile dysfunction in males. The company has also announced April 29, 2012 as the target date for the FDA to complete its review of the product’s NDA.

There has been a previously announced report of the phase 3 trials with the product avanafil that talks of results that it yielded. The report said that patients who were treated with avanafil saw noteworthy improvement in the erectile function as compared to placebo. A program called the avanafil development program was conducted that included over 1,350 patients and avanafil was displayed as one of the most tolerated and effective drug in treating patients with General ED and diabetics patients with ED. The company also said in its report that results observed in the phase 3 also confirmed by the long-term safety study.

News by Generic Viagra